Patents by Inventor Nicholas J. Lawrence

Nicholas J. Lawrence has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240010634
    Abstract: The present disclosure provides anti-cancer compounds and uses thereof, more particularly inhibitors of ACK1 tyrosine kinase and their use in the treatment of cancer.
    Type: Application
    Filed: August 16, 2021
    Publication date: January 11, 2024
    Inventors: Nicholas J. LAWRENCE, Harshani Rithma LAWRENCE, Derek DUCKETT, Gary REUTHER
  • Publication number: 20230348518
    Abstract: This disclosure provides compounds for the treatment of medical disorders such as cancer, and more particularly compounds which find use as inhibitors of CMG helicase.
    Type: Application
    Filed: October 5, 2021
    Publication date: November 2, 2023
    Inventors: Mark ALEXANDROW, Nicholas J. LAWRENCE, Harshani Rithma LAWRENCE
  • Publication number: 20230303499
    Abstract: The present disclosure provides anti-cancer compounds and uses thereof, more particularly inhibitors of ACK1 tyrosine kinase and their use in the treatment of cancer.
    Type: Application
    Filed: August 16, 2021
    Publication date: September 28, 2023
    Inventors: Nicholas J. LAWRENCE, Harshani Rithma LAWRENCE, Derek DUCKETT, Gary REUTHER
  • Publication number: 20230295129
    Abstract: The present disclosure provides anti-cancer compounds and uses thereof, more particularly inhibitors of ACK1 tyrosine kinase and their use in the treatment of cancer.
    Type: Application
    Filed: August 16, 2021
    Publication date: September 21, 2023
    Inventors: Nicholas J. LAWRENCE, Harshani Rithma LAWRENCE, Derek DUCKETT, Gary REUTHER
  • Patent number: 11730726
    Abstract: Disclosed are small molecules against cereblon to enhance effector T cell function. Methods of making these molecules and methods of using them to treat various disease states are also disclosed.
    Type: Grant
    Filed: July 11, 2019
    Date of Patent: August 22, 2023
    Assignee: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.
    Inventors: Pearlie Burnette, Nicholas J. Lawrence, Harshani Lawrence
  • Publication number: 20230234924
    Abstract: Binding of the transcriptional co-activator, YAP1, to the transcription factor Oct4, induces Sox2, which is a transcription actor necessary for the self-renewal of stem-like cells from non-small cell lung cancer. The WW domain of YAP1 binds to the PPxY motif of Oct4 to induce Sox2. Delivering a peptide corresponding to the WW domain could prevent the induction of Sox2 and sternness. Similarly, peptides and mimetics of the PPxY motif would be able to inhibit sternness. Disclosed are compounds that affect the Yap1:Oct4 interaction.
    Type: Application
    Filed: December 19, 2022
    Publication date: July 27, 2023
    Inventors: Srikumar CHELLAPPAN, Nicholas J. LAWRENCE, Sujeewa Ranatunga Mahanthe MUDIYANSELAGE
  • Publication number: 20230226035
    Abstract: Disclosed are small molecules against cereblon to enhance effector T cell function. Methodos of making thes molecules and methods of using them to treat various disease states are also disclosed.
    Type: Application
    Filed: June 7, 2022
    Publication date: July 20, 2023
    Inventors: Pearlie Burnette, Harshani Lawrence, Nicholas J. Lawrence
  • Publication number: 20230201191
    Abstract: The subject invention concerns a compound and compositions having activity as an inhibitor of Stat3 protein and methods of using the compound and compositions. In one embodiment, a compound of the invention has the structure shown in formula I, formula II, or formula III. The subject invention also concerns methods of using the compounds and compositions of the invention.
    Type: Application
    Filed: January 31, 2023
    Publication date: June 29, 2023
    Inventors: SAID M. SEBTI, NICHOLAS J. LAWRENCE, JAMES TURKSON
  • Patent number: 11685725
    Abstract: Binding of the transcriptional co-activator, YAP1, to the transcription factor Oct4, induces Sox2, which is a transcription actor necessary for the self-renewal of stem-like cells from non-small cell lung cancer. The WW domain of YAP1 binds to the PPxY motif of Oct4 to induce Sox2. Delivering a peptide corresponding to the WW domain could prevent the induction of Sox2 and sternness. Similarly, peptides and mimetics of the PPxY motif would be able to inhibit sternness. Disclosed are compounds that affect the Yap1:Oct4 interaction.
    Type: Grant
    Filed: March 14, 2019
    Date of Patent: June 27, 2023
    Assignee: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.
    Inventors: Srikumar Chellappan, Nicholas J. Lawrence, Sujeewa Ranatunga Mahanthe Mudiyanselage
  • Patent number: 11643396
    Abstract: Disclosed herein are compounds that are inhibitors of BDR4 and their use in the treatment of cancer. Methods of screening for selective inhibitors of BDR4 are also disclosed. In certain aspects, disclosed are compounds of Formula I through IV.
    Type: Grant
    Filed: June 5, 2020
    Date of Patent: May 9, 2023
    Assignee: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.
    Inventors: Ernst Schönbrunn, Nicholas J. Lawrence, Harshani R. Lawrence
  • Patent number: 11571418
    Abstract: The subject invention concerns a compound and compositions having activity as an inhibitor of Stat3 protein and methods of using the compound and compositions. In one embodiment, a compound of the invention has the structure shown in formula I, formula II, or formula III. The subject invention also concerns methods of using the compounds and compositions of the invention.
    Type: Grant
    Filed: October 22, 2020
    Date of Patent: February 7, 2023
    Assignees: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC., UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC.
    Inventors: Said M. Sebti, Nicholas J. Lawrence, James Turkson
  • Patent number: 11530182
    Abstract: Binding of the transcriptional co-activator, YAP1, to the transcription factor Oct4, induces Sox2, which is a transcription actor necessary for the self-renewal of stem-like cells from non-small cell lung cancer. The WW domain of YAP1 binds to the PPxY motif of Oct4 to induce Sox2. Delivering a peptide corresponding to the WW domain could prevent the induction of Sox2 and stemness. Similarly, peptides and mimetics of the PPxY motif would be able to inhibit sternness. Disclosed are compounds that affect the Yap1:Oct4 interaction.
    Type: Grant
    Filed: December 30, 2020
    Date of Patent: December 20, 2022
    Assignee: H. Lee Moffitt Cancer Center and Research Institute, Inc.
    Inventors: Srikumar Chellappan, Nicholas J. Lawrence, Sujeewa Ranatunga Mahanthe Mudiyanselage
  • Publication number: 20220362229
    Abstract: Disclosed are small molecules against cereblon to enhance effector T cell function. Methods of making these molecules and methods of using them to treat various disease states are also disclosed.
    Type: Application
    Filed: July 11, 2019
    Publication date: November 17, 2022
    Inventors: Pearlie BURNETTE, Nicholas J. LAWRENCE, Harshani LAWRENCE
  • Patent number: 11395820
    Abstract: Disclosed are small molecules against cereblon to enhance effector T cell function. Methods of making these molecules and methods of using them to treat various disease states are also disclosed.
    Type: Grant
    Filed: March 16, 2017
    Date of Patent: July 26, 2022
    Assignee: H. Lee Moffitt Cancer Center and Research Institute, Inc.
    Inventors: Pearlie Burnette, Harshani Lawrence, Nicholas J. Lawrence
  • Publication number: 20220119370
    Abstract: Disclosed herein are compounds that are inhibitors of BDR4 and their use in the treatment of cancer. Methods of screening for selective inhibitors of BDR4 are also disclosed. In certain aspects, disclosed are compounds of Formula I through IV.
    Type: Application
    Filed: September 9, 2019
    Publication date: April 21, 2022
    Inventors: Ernst SCHÖNBRUNN, Nicholas J. LAWRENCE, Harshani R. LAWRENCE, Gary REUTHER
  • Publication number: 20210363128
    Abstract: Binding of the transcriptional co-activator, YAP1, to the transcription factor Oct4, induces Sox2, which is a transcription actor necessary for the self-renewal of stem-like cells from non-small cell lung cancer. The WW domain of YAP1 binds to the PPxY motif of Oct4 to induce Sox2. Delivering a peptide corresponding to the WW domain could prevent the induction of Sox2 and sternness. Similarly, peptides and mimetics of the PPxY motif would be able to inhibit sternness. Disclosed are compounds that affect el the Yap1:Oct4 interaction.
    Type: Application
    Filed: March 14, 2019
    Publication date: November 25, 2021
    Inventors: Srikumar CHELLAPPAN, Nicholas J. LAWRENCE, Sujeewa Ranatunga Mahanthe MUDIYANSELAGE
  • Publication number: 20210355088
    Abstract: Disclosed herein are compounds that are inhibitors of BDR4 and their use in the treatment of cancer. Methods of screening for selective inhibitors of BDR4 are also disclosed. In certain aspects, disclosed are compounds of Formula I, II, and II.
    Type: Application
    Filed: September 9, 2019
    Publication date: November 18, 2021
    Inventors: Ernst SCHÖNBRUNN, Nicholas J. LAWRENCE, Harshani R. LAWRENCE, Gary REUTHER
  • Publication number: 20210177836
    Abstract: The subject invention concerns a compound and compositions having activity as an inhibitor of Stat3 protein and methods of using the compound and compositions. In one embodiment, a compound of the invention has the structure shown in formula I, formula II, or formula III. The subject invention also concerns methods of using the compounds and compositions of the invention.
    Type: Application
    Filed: October 22, 2020
    Publication date: June 17, 2021
    Inventors: SAID M. SEBTI, NICHOLAS J. LAWRENCE, JAMES TURKSON
  • Publication number: 20210177825
    Abstract: Disclosed are small molecules against cereblon to enhance effector T cell function. Methods of making these molecules and methods of using them to treat various disease states are also disclosed.
    Type: Application
    Filed: March 16, 2017
    Publication date: June 17, 2021
    Inventors: Pearlie Burnette, Harshani Lawrence, Nicholas J. Lawrence
  • Publication number: 20210130297
    Abstract: Binding of the transcriptional co-activator, YAP1, to the transcription factor Oct4, induces Sox2, which is a transcription actor necessary for the self-renewal of stem-like cells from non-small cell lung cancer. The WW domain of YAP1 binds to the PPxY motif of Oct4 to induce Sox2. Delivering a peptide corresponding to the WW domain could prevent the induction of Sox2 and stemness. Similarly, peptides and mimetics of the PPxY motif would be able to inhibit sternness. Disclosed are compounds that affect the Yap1:Oct4 interaction.
    Type: Application
    Filed: December 30, 2020
    Publication date: May 6, 2021
    Inventors: Srikumar CHELLAPPAN, Nicholas J. LAWRENCE, Sujeewa Ranatunga Mahanthe MUDIYANSELAGE